Cornerstone Investment Partners LLC Purchases New Shares in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Cornerstone Investment Partners LLC acquired a new position in Organogenesis Holdings Inc. (NASDAQ:ORGO) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 50,502 shares of the company’s stock, valued at approximately $162,000.

Several other large investors have also bought and sold shares of ORGO. JPMorgan Chase & Co. increased its stake in shares of Organogenesis by 107.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 205,943 shares of the company’s stock valued at $589,000 after acquiring an additional 106,823 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in Organogenesis by 54.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,950,849 shares of the company’s stock valued at $9,443,000 after purchasing an additional 1,035,120 shares in the last quarter. Verition Fund Management LLC raised its holdings in Organogenesis by 542.8% in the third quarter. Verition Fund Management LLC now owns 78,690 shares of the company’s stock worth $225,000 after purchasing an additional 66,448 shares during the period. Barclays PLC raised its holdings in Organogenesis by 251.7% in the third quarter. Barclays PLC now owns 94,809 shares of the company’s stock worth $271,000 after purchasing an additional 67,855 shares during the period. Finally, FMR LLC increased its position in shares of Organogenesis by 34.2% in the 3rd quarter. FMR LLC now owns 173,595 shares of the company’s stock valued at $496,000 after buying an additional 44,199 shares in the last quarter. 49.57% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Gary S. Gillheeney sold 18,416 shares of the company’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $3.65, for a total transaction of $67,218.40. Following the completion of the transaction, the chief executive officer now directly owns 3,400,778 shares of the company’s stock, valued at $12,412,839.70. This represents a 0.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last three months, insiders have sold 278,116 shares of company stock worth $991,190. Company insiders own 36.90% of the company’s stock.

Organogenesis Stock Down 6.8 %

Shares of Organogenesis stock opened at $5.04 on Wednesday. The company has a market capitalization of $639.21 million, a P/E ratio of -84.00 and a beta of 1.66. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. The business has a 50-day moving average of $3.51 and a two-hundred day moving average of $3.29. Organogenesis Holdings Inc. has a 1 year low of $2.17 and a 1 year high of $6.71.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.